Brad Saar Joins Sonablate Board to Advance Non-Invasive Prostate Cancer Treatments

Sonablate, a leader in non-invasive prostate cancer treatment using high-intensity focused ultrasound (HIFU), has appointed Brad Saar, former president of Stryker’s Medical Division, to its Board of Directors. Saar, who brings over 30 years of medical technology leadership experience, aims to support the growth of HIFU technology and the expansion of precision sound medicine. As interest in non-invasive treatment options rises, Sonablate focuses on increasing physician adoption and patient awareness of HIFU as a viable alternative to traditional surgery and radiation. The company plans to engage with medical professionals at upcoming industry conferences to promote educational discussions around HIFU effectiveness and patient selection.